Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
Nowadays immunotherapy is a crucial option in the treatment of non-small cell lung cancer. There are a lot of actual options of the first-line therapy for the patients with metastatic lung cancer, including dual immunological blockade of PD-1/PD-L1 and CTLA-4 pathways. This review is an attempt to c...
Enregistré dans:
Auteurs principaux: | Denis I. Yudin, Konstantin K. Laktionov, Liudmila V. Laktionova, Valeriy V. Breder |
---|---|
Format: | article |
Langue: | RU |
Publié: |
IP Habib O.N.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a92e51c914374d90b0dcf921ac158329 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
par: Maria V. Deligiorgi, et autres
Publié: (2021) -
The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
par: Vladislav O. Sarzhevskiy, et autres
Publié: (2021) -
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
par: Virginia Liberini, et autres
Publié: (2021) -
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
par: Chi Yan, et autres
Publié: (2021) -
Immunotherapeutic Advances for NSCLC
par: Massafra M, et autres
Publié: (2021)